Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


Hepsin promotes prostate cancer progression and metastasis.

Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V.

Cancer Cell. 2004 Aug;6(2):185-95.


Hepsin paradox reveals unexpected complexity of metastatic process.

Vasioukhin V.

Cell Cycle. 2004 Nov;3(11):1394-7. Epub 2004 Nov 28.


Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V.

J Biol Chem. 2008 Nov 7;283(45):30576-84. doi: 10.1074/jbc.M802312200. Epub 2008 Sep 9.


Hepsin and prostate cancer.

Wu Q, Parry G.

Front Biosci. 2007 Sep 1;12:5052-9. Review.


Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R.

Prostate. 2010 May 1;70(6):591-600. doi: 10.1002/pros.21093.


Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.

Tang X, Mahajan SS, Nguyen LT, Béliveau F, Leduc R, Simon JA, Vasioukhin V.

Oncotarget. 2014 Mar 15;5(5):1352-62.


Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.

Valkenburg KC, Hostetter G, Williams BO.

Prostate. 2015 Oct;75(14):1579-85. doi: 10.1002/pros.23032. Epub 2015 Jul 2.


Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, Mertens D, Sültmann H, Wittig R.

Neoplasia. 2011 Jul;13(7):579-89.


Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.

Li W, Wang BE, Moran P, Lipari T, Ganesan R, Corpuz R, Ludlam MJ, Gogineni A, Koeppen H, Bunting S, Gao WQ, Kirchhofer D.

Cancer Res. 2009 Nov 1;69(21):8395-402. doi: 10.1158/0008-5472.CAN-09-1995. Epub 2009 Oct 20.


Pro-urokinase-type plasminogen activator is a substrate for hepsin.

Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D.

J Biol Chem. 2006 Oct 13;281(41):30439-46. Epub 2006 Aug 14.


Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.

Xuan JA, Schneider D, Toy P, Lin R, Newton A, Zhu Y, Finster S, Vogel D, Mintzer B, Dinter H, Light D, Parry R, Polokoff M, Whitlow M, Wu Q, Parry G.

Cancer Res. 2006 Apr 1;66(7):3611-9.


Expression profiling reveals hepsin overexpression in prostate cancer.

Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J.

Cancer Res. 2001 Aug 1;61(15):5692-6.


Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2α phosphorylation in prostate cancer.

Zhang C, Zhang M, Wu Q, Peng J, Ruan Y, Gu J.

Cell Signal. 2015 Apr;27(4):789-97. doi: 10.1016/j.cellsig.2014.12.020. Epub 2015 Jan 7.


Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.

Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA.

J Urol. 2003 Apr;169(4):1316-9.


Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues.

Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR.

Br J Cancer. 2005 Jun 20;92(12):2171-80.


The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS.

Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13.


Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.

Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP.

J Biol Chem. 2005 Jul 1;280(26):25134-45. Epub 2005 Mar 30.


Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.

Ko CJ, Huang CC, Lin HY, Juan CP, Lan SW, Shyu HY, Wu SR, Hsiao PW, Huang HP, Shun CT, Lee MS.

Cancer Res. 2015 Jul 15;75(14):2949-60. doi: 10.1158/0008-5472.CAN-14-3297. Epub 2015 May 27.


The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.

Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, Nelson PS.

J Pathol. 2008 Jun;215(2):118-25. doi: 10.1002/path.2330.


HEPSIN inhibits cell growth/invasion in prostate cancer cells.

Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S.

Cancer Res. 2002 Dec 1;62(23):6812-6.

Supplemental Content

Support Center